Wearable Tech Proves Menopause Drug Veozah Restores Sleep Quality

NORTHBROOK, IL – October 02, 2026 – The longevity economy isn't just about living longer; it's about optimizing the quality of those extended years. For decades, menopausal women have navigated a medical landscape that often dismissed their most disruptive symptoms, particularly the severe sleep fragmentation that derails cognitive function and daily productivity. Today, the convergence of targeted neuro-therapeutics and objective digital tracking is rewriting that narrative. Astellas Pharma has unveiled preliminary real-world data from its Phase 4 OPTION-VMS study at the 2026 International Menopause Society (IMS) World Congress, demonstrating that its non-hormonal drug VEOZAH (fezolinetant 45mg) dramatically improves sleep outcomes alongside the reduction of vasomotor symptoms (VMS). By utilizing medical-grade wearables, the study bridges the gap between subjective patient anecdotes and hard, actigraphy-derived data, marking a pivotal moment in women's health strategy and showcasing exactly how technological integration improves lives.

Data on the Wrist: Validating Sleep Architecture

Sleep disturbances are among the most universally reported and debilitating symptoms of the menopausal transition, affecting an estimated 40 to 60 percent of women. The physiological toll is immense; women experiencing moderate to severe hot flashes are almost three times more likely to report frequent nighttime awakenings compared to those without VMS. Until recently, clinical validation for symptom relief relied heavily on subjective patient diaries, which can be prone to recall bias. Astellas took a decidedly modern route with the OPTION-VMS study, employing ActiGraph LEAP medical-grade wearables to map objective sleep architecture in routine clinical practice.

The distinction between consumer-grade fitness trackers and medical-grade actigraphy is critical here. Research-grade devices undergo rigorous validation against polysomnography—the clinical gold standard for sleep assessment—ensuring highly accurate monitoring of sleep-wake patterns in natural environments. The results from this robust tracking are striking. At week 12, the study's primary endpoint, women treated with fezolinetant saw a mean reduction of 2.6 nighttime awakenings per night. Furthermore, objective measures of sleep quality—including wakefulness after sleep onset (WASO), sleep efficiency, and sleep latency—showed statistically significant improvements starting as early as week 4.

Patient-reported outcomes mirrored the digital data perfectly. Scores on the PROMIS Sleep Disturbance scale shifted from the "mild disturbance" range at baseline into the "no sleep disturbance" category by the fourth week, maintaining that improvement through week 12. Dr. Shayna Mancuso, Executive Medical Director and Head of U.S. Medical Affairs for Women's Health at Astellas, noted, "By evaluating women's experiences in routine clinical practice, we are building a deeper understanding of the outcomes that matter most to women and their clinicians." This fusion of biological intervention and digital verification sets a new standard for how the pharmaceutical industry measures and proves the efficacy of quality-of-life drugs.

Beyond Hormones: A Lifeline for High-Risk Patients

To understand the strategic importance of this development, one must look at the glaring gaps in traditional menopause care. Hormone replacement therapy (HRT) has long been the gold standard for alleviating VMS, but it remains strictly contraindicated for a massive and growing demographic: survivors of hormone-receptor-positive breast cancer and women with specific cardiovascular or thromboembolic risks. For these women, the transition into menopause often brings a sudden, severe onset of hot flashes and night sweats, frequently compounded by the very endocrine therapies designed to keep their cancer at bay.

VEOZAH operates on an entirely different physiological mechanism, representing a true paradigm shift. As a first-in-class selective neurokinin 3 (NK3) receptor antagonist, it directly targets the brain's temperature control center. By blocking neurokinin B binding on the kisspeptin/neurokinin/dynorphin (KNDy) neurons in the hypothalamus, it neutralizes the biological trigger of hot flashes without introducing systemic hormones.

The OPTION-VMS study specifically evaluated women aged 40 to 75 in real-world settings, notably including participants with non-metastatic breast cancer who were receiving stable adjuvant endocrine therapy. While the initial observational enrollment saw 998 women across 50 U.S. sites, the final analysis cohort included 201 women specifically prescribed fezolinetant. Providing a clinically validated, non-hormonal off-ramp for these high-risk patients is more than a medical breakthrough; it is a strategic imperative. Ensuring that surviving cancer does not mean sacrificing a decade of restorative sleep and daily comfort is a cornerstone of the modern longevity economy.

Commercial Realities and Clinical Hurdles

Despite the compelling clinical narrative and the high-tech validation of its benefits, VEOZAH faces a complex commercial reality as it scales globally. The real-world data reinforces its profound efficacy, but routine clinical practice must also seamlessly accommodate the drug's strict safety monitoring requirements. Because of potential hepatic risks, the FDA mandates baseline and periodic liver panel testing for patients on fezolinetant—specifically monthly for the first three months, and again at months six and nine.

In the OPTION-VMS preliminary analysis, hepatic laboratory findings were encouragingly mild and infrequent. Investigators reported only two cases of non-serious, mildly elevated liver tests, neither of which led to treatment or study discontinuation. However, in the broader healthcare market, the logistical friction of frequent blood draws can deter both busy prescribers and convenience-seeking patients. Furthermore, as an innovative therapy, VEOZAH must navigate a challenging payer landscape where established, albeit off-label and often less effective, non-hormonal alternatives like SSRIs, SNRIs, and gabapentin are available as highly inexpensive generics.

Astellas is clearly banking on the undeniable superiority of targeted efficacy and objective quality-of-life improvements to justify its premium market positioning and overcome these adoption hurdles. Prof. Marla Shapiro, lead author of the OPTION-VMS oral presentation, emphasized the broader impact of this strategy: "Hot flashes and night sweats can have a far-reaching impact on women's daily lives, including their sleep, quality of life and overall well-being. These preliminary real-world findings add to the growing body of evidence from OPTION-VMS, demonstrating improvements in bothersome vasomotor symptoms and sleep outcomes among women treated with fezolinetant."

As Astellas continues to gather longitudinal data from parallel real-world studies like GRACE in Germany and ADELE-AU in Australia, the company's global strategy crystallizes. By leveraging objective digital health metrics to prove that targeted neuro-therapeutics can literally give women their nights back, the pharmaceutical giant is building an ironclad evidence matrix. This approach is meticulously designed to overcome administrative hurdles, satisfy cautious payers, and secure a foundational role in the future of global menopause management.